17h40 Anderson de Oliveira Galvão
Transcrição
17h40 Anderson de Oliveira Galvão
Vigilância Ativa no Câncer de Próstata Comparação dos Resultados com Tratamentos Locais Conflito de Interesse Nunca recebi qualquer forma de pagamento ou auxílio financeiro de entidade pública ou privada para pesquisa ou desenvolvimento de métodos, diagnósticos e terapêuticos ou ainda, honorários como consultor de indústria farmacêutica. NCCN – 3.2016 Vigilância Ativa - Active Surveillance aims to achieve correct timing for curative treatment. Welty, C.J. et al Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4 Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4 Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4 Timothy J. W. et al. The New England Journal of Medicine 07-2012 – PIVOT Matthew et al. The New England Journal of Medicine 01-2013 - PCOS Comparativo de Técnicas? Klotz L. et al Journal of Clinical Oncology 01-2015 Godtman R. A. et al. European Urology 03-2016 In Press - Göteborg Godtman R. A. et al. European Urology 03-2016 In Press - Göteborg Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden Auffenberg G. B. et al. The Journal of Urology 05-2016 – Manuscript Carter B. H. et al. Journal of Clinical Oncology 06-2011 – Johns Hopkins Bokhorst L. P. et al. European Urology 06-2016 In Press - PRIAS Christopher J. D. et al. European Urology 10-2015 Perspectivas Futuras Lane A. J. and Donovan J. L.et al Lancet 08-2014 ProtecT Trial AS in selected patients is feasible with an estimated 10‐year PCa‐specific survival, reported between 96% and 100% for both low‐ and intermediate‐risk patients. However, the long natural history of PCa must be born in mind, and even non‐PSA detected localized PCa has an indolente course during the first 10–15 years with a cause specific survival >90% when managed on WW. Frederik B. Thomsen [email protected]